Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.

doi:10.1016/J.JHEP.2012.12.011

Home
/
Papers
/
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.

Journal Article•DOI•

Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.

Thomas Reiberger¹, Arnulf Ferlitsch¹, Berit A. Payer¹, Mattias Mandorfer¹, B. Heinisch¹, Hubert Hayden¹, Frank Lammert², Michael Trauner¹, Markus Peck-Radosavljevic¹, Harald Vogelsang¹ - Show less +6 more•Institutions (2)

Medical University of Vienna¹, Saarland University²

01 May 2013-Journal of Hepatology (Elsevier)-Vol. 58, Iss: 5, pp 911-921

TL;DR: NSBB treatment ameliorates gastroduodenal/intestinal permeability and reduces bacterial translocation partially independent of their hemodynamic effects on portal pressure, which may contribute to a reduced risk of variceal bleeding.

read less

About: This article is published in Journal of Hepatology.The article was published on 2013-05-01. It has received 270 citations till now. The article focuses on the topics: Portal venous pressure & Intestinal permeability.

...read moreread less

Citations

PDF

Open Access

More filters

Journal Article•DOI•

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

[...]

Paolo Angeli, Mauro Bernardi, Càndid Villanueva, Claire Francoz, Rajeshwar P. Mookerjee, Jonel Trebicka, Aleksander Krag, Wim Laleman, Pere Ginès - Show less +5 more

01 Aug 2018-Journal of Hepatology

TL;DR: The panel of experts, having emphasised the importance of initiating aetiologic treatment for any degree of hepatic disease at the earliest possible stage, extended its work to all the complications of cirrhosis which had not been covered by the European Association for the Study of the Liver guidelines.

...read moreread less

1,534 citations

Journal Article•DOI•

Changes of Intestinal Functions in Liver Cirrhosis

[...]

Hiroshi Fukui¹, Reiner Wiest•Institutions (1)

Nara Medical University¹

08 Mar 2016

TL;DR: This review summarizes major achievements regarding intestinal dysfunction in cirrhosis for future gastroenterology research and suggests that delayed small bowel transit in liver Cirrhosis may lead to SIBO, which could contribute to the symptoms of abdominal pain and diarrhea.

...read moreread less

Abstract: Background: Understanding of the gut-liver axis is important for the up-to-date management of liver cirrhosis, and changes of intestinal functions form the core o

...read moreread less

1,311 citations

Journal Article•DOI•

Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance

[...]

Agustín Albillos¹, Agustín Albillos², M. Lario², Melchor Alvarez-Mon¹, Melchor Alvarez-Mon² - Show less +1 more•Institutions (2)

Carlos III Health Institute¹, University of Alcalá²

01 Dec 2014-Journal of Hepatology

TL;DR: Cirrhosis-associated immune dysfunction phenotypes switch from predominantly "pro-inflammatory" to predominantly "immunodeficient" in patients with stable ascitic cirrhosis and in Patients with severely decompensated cirrhoses and extra-hepatic organ failure (e.g. acute-on-chronic liver failure), respectively.

...read moreread less

795 citations

Journal Article•DOI•

Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013

[...]

Rajiv Jalan¹, Javier Fernández², Reiner Wiest, Bernd Schnabl³, Richard Moreau⁴, Paolo Angeli⁵, Vanessa Stadlbauer⁶, Thierry Gustot⁷, Mauro Bernardi⁸, Rafael Cantón, Agustín Albillos, Frank Lammert⁹, Alexander Wilmer¹⁰, Rajeshwar P. Mookerjee¹, Jordi Vila¹¹, R. Garcia-Martinez², Julia Wendon¹², José Such², Juan Córdoba², Arun J. Sanyal¹³, Guadalupe Garcia-Tsao¹⁴, Vicente Arroyo², Andrew K. Burroughs¹⁵, Pere Ginès² - Show less +20 more•Institutions (15)

Royal Free Hospital¹, Carlos III Health Institute², University of California, San Diego³, Paris Diderot University⁴, University of Padua⁵, University of Graz⁶, Université libre de Bruxelles⁷, University of Bologna⁸, Saarland University⁹, Katholieke Universiteit Leuven¹⁰, University of Barcelona¹¹, King's College London¹², Virginia Commonwealth University¹³, Yale University¹⁴, University College London¹⁵

01 Jun 2014-Journal of Hepatology

TL;DR: An in-depth review and a position statement on bacterial infections in cirrhosis are reported, which suggest that research on biomarkers of early infection may be useful in early diagnosis and treatment of infections.

...read moreread less

664 citations

Cites background from "Non-selective betablocker therapy d..."

...Non-antibiotic strategies have been studied as a potential alternative to quinolones in the prophylaxis of bacterial infections in cirrhosis but evidence published so far is still limited [159–161,54,162]....
[...]

Journal Article•DOI•

Pathological bacterial translocation in liver cirrhosis.

[...]

Reiner Wiest, Melissa A. E. Lawson¹, Markus B. Geuking¹•Institutions (1)

University of Bern¹

01 Jan 2014-Journal of Hepatology

TL;DR: There appears to exist a hierarchy of three barriers against pathological BT, each of which encompasses a distinct set of mechanisms and involves the rapid detection and killing of bacteria that manage to penetrate.

...read moreread less

586 citations

Cites background from "Non-selective betablocker therapy d..."

...In principle however, level of portal hypertension [34] and liver insufficiency [187–189] are the driving forces for BT....
[...]
...Additional proposed beneficial effects of sympathectomy are accelerated intestinal transit time [92], prevention of gram-negative bacterial overgrowth [155] and improvement in gastrointestinal permeability [34]....
[...]

1
2
3
4
…
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Collapse

References

PDF

Open Access

More filters

Journal Article•DOI•

Revising consensus in portal hypertension: Report of the Baveno V Consensus Workshop on methodology of diagnosis and therapy in Portal Hypertension

[...]

Roberto de Franchis¹•Institutions (1)

University of Milan¹

01 Jul 2005-Journal of Hepatology

TL;DR: A Baveno V workshop was held on May 21–22, 2010, attended by many of the experts responsible for most of the major achievements of the last years in this field, and produced consensus statements on some important points, although some issues remained unsettled.

...read moreread less

2,074 citations

Journal Article•DOI•

Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining Prognosis

[...]

Vasiliki Arvaniti¹, Gennaro D'Amico, Giuseppe Fede¹, Pinelopi Manousou¹, Emmanuel Tsochatzis¹, M. Pleguezuelo¹, Andrew K. Burroughs¹ - Show less +3 more•Institutions (1)

University College London¹

01 Oct 2010-Gastroenterology

TL;DR: In patients with cirrhosis, infections increase mortality 4-fold; 30% of patients die within 1 month after infection and another 30% die by 1 year; prospects with prolonged follow-up evaluation and to evaluate preventative strategies are needed.

...read moreread less

929 citations

Journal Article•DOI•

The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule

[...]

Yasuko Iwakiri¹, Roberto J. Groszmann¹•Institutions (1)

Yale University¹

01 Feb 2006-Hepatology

TL;DR: This review summarizes three major areas: first, clinical observation in patients; second, experimental models used to study the hyperdynamic circulatory syndrome; and third, the vasodilator molecules that play roles in vascular abnormalities observed in portal hypertension.

...read moreread less

507 citations

Journal Article•DOI•

Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.

[...]

Juan G. Abraldes¹, Ilaria Tarantino¹, Juan Turnes¹, Juan Carlos García-Pagán¹, Juan Rodés¹, Jaime Bosch¹ - Show less +2 more•Institutions (1)

University of Barcelona¹

01 Apr 2003-Hepatology

TL;DR: In cirrhotic patients receiving pharmacologic treatment for prevention of variceal rebleeding, a decrease in HVPG ≥20% or to ≤12 mm Hg is associated with a marked reduction in the long‐term risk of developing complications of portal hypertension and with improved survival.

...read moreread less

497 citations

Journal Article•DOI•

Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites

[...]

Thomas Sersté¹, Christian Melot, Claire Francoz¹, Claire Francoz², François Durand¹, François Durand², Pierre-Emmanuel Rautou¹, Dominique Valla², Dominique Valla¹, Richard Moreau², Richard Moreau¹, Didier Lebrec¹, Didier Lebrec² - Show less +9 more•Institutions (2)

French Institute of Health and Medical Research¹, Paris Diderot University²

01 Sep 2010-Hepatology

TL;DR: The use of beta‐blockers is associated with poor survival in patients with refractory ascites, and results suggest that beta‐ blockers should be contraindicated in these patients.

...read moreread less

472 citations

"Non-selective betablocker therapy d..." refers background in this paper

...An interesting hypothesis was recently introduced that the benefit in survival gained by NSBB treatment may be of particular relevance during a certain ‘‘time-window’’ in the pre-decompensation stage of cirrhosis [19], which might close at the stage of refractory ascites [39]....
[...]
...However, we may speculate that the positive effects of NSBB treatment observed in patients with compensated cirrhosis without refractory ascites in terms of improving intestinal permeability and decreasing bacterial translocation may be overruled by their detrimental role on systemic/renal hemodynamics in the clinical setting of refractory ascites [39]....
[...]
...In regard to the potential deleterious effects of NSBB treatment in patients with refractory ascites, the net effect of NSBB on survival in cirrhotic patients with and without ascites, being a risk for progressive cardiac and/or renal failure, has to be prospectively evaluated [19,39]....
[...]